A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,800 shares of PRQR stock, worth $3,384. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,800
Previous 36,000 95.0%
Holding current value
$3,384
Previous $82,000 97.56%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.65 - $2.39 $45,610 - $66,066
-27,643 Reduced 60.08%
18,365 $30,000
Q1 2024

May 15, 2024

SELL
$1.89 - $2.85 $60,117 - $90,652
-31,808 Reduced 40.88%
46,008 $105,000
Q4 2023

Feb 14, 2024

BUY
$1.15 - $2.21 $89,488 - $171,973
77,816 New
77,816 $154,000
Q2 2023

Aug 14, 2023

BUY
$1.62 - $2.32 $27,561 - $39,470
17,013 Added 17.05%
116,792 $189,000
Q1 2023

May 15, 2023

BUY
$1.99 - $3.66 $198,560 - $365,191
99,779 New
99,779 $212,000
Q2 2022

Aug 15, 2022

SELL
$0.56 - $1.0 $7,310 - $13,054
-13,054 Reduced 5.87%
209,215 $162,000
Q4 2021

Feb 14, 2022

BUY
$6.58 - $8.44 $855,814 - $1.1 Million
130,063 Added 141.06%
222,269 $1.78 Million
Q3 2021

Nov 15, 2021

BUY
$5.16 - $8.47 $175,832 - $288,623
34,076 Added 58.62%
92,206 $772,000
Q2 2021

Aug 16, 2021

BUY
$5.75 - $7.59 $171,085 - $225,832
29,754 Added 104.86%
58,130 $391,000
Q1 2021

May 17, 2021

BUY
$4.14 - $9.22 $117,476 - $261,626
28,376 New
28,376 $188,000
Q4 2019

Feb 14, 2020

SELL
$5.84 - $10.51 $385,416 - $693,617
-65,996 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$5.76 - $9.44 $132,312 - $216,846
22,971 Added 53.39%
65,996 $380,000
Q2 2019

Aug 14, 2019

SELL
$9.1 - $15.55 $357,757 - $611,332
-39,314 Reduced 47.75%
43,025 $391,000
Q1 2019

May 15, 2019

BUY
$12.5 - $18.48 $379,587 - $561,182
30,367 Added 58.43%
82,339 $0
Q4 2018

Feb 14, 2019

BUY
$15.25 - $22.4 $792,573 - $1.16 Million
51,972 New
51,972 $820,000

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $134M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.